The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I Dont think they care..
to me its game over here..will delist.. and thats that.
this is how you cover everything :)
Accordingly, in further aspects, the invention provides:
2.8 A method of treating a disease or condition in a subject in need thereof, wherein the disease is selected from an inflammatory disease or condition, an immunological disease or condition, an allergic disease or disorder, a transplant rejection and Graft-versus host disease, or a disease or condition selected from sepsis and septic shock,
just speaking aloud..
SAR have been really smart in obtaining Patent protection, by making 2 seperate patent applications for SDC1802
Earlier this year, Patent was granted for the immune side - that patent absolutely covers so many indications.. no wonder SAR had a bit of trouble with the examiner and a lot of back and forth, if you read up the scope of the patent, it is mid boggling
and now they covered the cancer side.
all i can say is, you can lead the horse to the water.....
interest- for what reason i dont know!
http://www.icr.ac.uk/our-research/researchers-and-teams/dr-anderson-wang